2083618-79-3
中文名稱
化合物 PDZ1I
英文名稱
1H-Cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide, N-[2,5-dimethyl-4-[[1-oxo-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propyl]amino]phenyl]-5,6,7,8-tetrahydro-8-oxo-
CAS
2083618-79-3
分子式
C28H26N8O4
分子量
538.56
MOL 文件
2083618-79-3.mol
更新日期
2025/04/26 21:41:27
2083618-79-3 結(jié)構(gòu)式
基本信息
中文別名
化合物 PDZ1I 英文別名
PDZ1i1H-Cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide, N-[2,5-dimethyl-4-[[1-oxo-3-(5-phenyl-1,3,4-oxadiazol-2-yl)propyl]amino]phenyl]-5,6,7,8-tetrahydro-8-oxo-
物理化學性質(zhì)
密度1.53±0.1 g/cm3(Predicted)
酸度系數(shù)(pKa)10.11±0.70(Predicted)
形態(tài)Solid
顏色White to off-white
應(yīng)用領(lǐng)域
用途一
PDZ1i, also known as 113B7, is an inhibitor of MDA-9/Syntenin activity. PDZ1i radiosensitized GBM cells. PDZ1i inhibited crucial GBM signaling involving FAK and mutant EGFR, EGFRvIII, and abrogated gains in secreted proteases, MMP-2 and MMP-9, following radiation. In an in vivo glioma model, PDZ1i resulted in smaller, less invasive tumors and enhanced survival. When combined with radiation, survival gains exceeded radiotherapy alone.